SCHEMBL14770645

SCHEMBL14770645

c1ccc(-c2cc(-c3cccc(-c4ccc5oc6ccc(-n7c8ccccc8c8ccccc87)cc6c5c4)n3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 5/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
MAPK1 P28482 2/20 0.35
HPGD P15428 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTPRF P10586 6/20 0.34
PTPN2 P17706 6/20 0.34
PTPN1 P18031 6/20 0.34
PLA2G2A P14555 3/20 0.33
PLA2G4A P47712 3/20 0.33
AHR P35869 1/20 0.33
PLA2G10 O15496 1/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14867943 0.94 KMT2A (0.38) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770633 0.93 PRKDC (0.36) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL10041340 0.93 KDM4E (0.38) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770629 0.92 KDM4E (0.38) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14733754 0.92 KDM4E (0.38) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770634 0.91 PRKDC (0.35) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770569 0.90 KDM4E (0.38) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL13471326 0.90 KMT2A (0.41) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770574 0.89 KDM4E (0.43) KMT2AMEN1RAB9AKDM4EL3MBTL1
SCHEMBL14770715 0.89 L3MBTL1 (0.37) KMT2AMEN1RAB9AKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND TDO2, AHR, NOC2L KMT2A 382/4885MEN1 2134/4885RAB9A 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.